APA

Fijal B. A., Guo Y., Li S. G., Ahl J., Goto T., Tanaka Y., Nisenbaum L. K. & Upadhyaya H. P. (20160622). CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. : Journal of clinical pharmacology.

Chicago

Fijal Bonnie A, Guo Yingying, Li Si G, Ahl Jonna, Goto Taro, Tanaka Yoko, Nisenbaum Laura K and Upadhyaya Himanshu P. 20160622. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. : Journal of clinical pharmacology.

Harvard

Fijal B. A., Guo Y., Li S. G., Ahl J., Goto T., Tanaka Y., Nisenbaum L. K. and Upadhyaya H. P. (20160622). CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. : Journal of clinical pharmacology.

MLA

Fijal Bonnie A, Guo Yingying, Li Si G, Ahl Jonna, Goto Taro, Tanaka Yoko, Nisenbaum Laura K and Upadhyaya Himanshu P. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. : Journal of clinical pharmacology. 20160622.